Acrometa Posts Record Revenue of S$69.5 Million for FY2023, Continues to Pursue New Opportunities in Co-Working Lab Space Business

SINGAPORE, Nov 29, 2023 – (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced its financial results for the 12 months ended 30 September 2023 (“FY2023”).

The Group’s revenue for FY2023 saw a 12% increase to S$69.5 million, a historical high for the Group, primarily attributed to the Engineering, Procurement and Construction (“EPC”) segment’s strong performance. Gross profit increased by 19% from S$9.8 million for FY2022 to S$11.7 million for FY2023, while gross profit margins improved from 15.7% for FY2022 to 16.8% in FY2023.

The Group’s continuing operations comprising of its specialist EPC and maintenance segments recorded a profit of S$2.2 million on the back of a 10.8% growth in revenue from S$62.3 million for FY2022 to S$69.0 million for FY2023. However, the operating environment remains challenging amidst increased operational costs in energy, labour, and materials as a result of inflationary pressures in the global economy.

In May 2023, the Group ventured into the co-working laboratory space segment through the acquisition of Life Science Incubator Pte Ltd (“LSI”), which currently manages a 6,500 sqft co-working laboratory space at The German Centre, Singapore. Under the Group’s leadership, LSI has made significant inroads with new partnerships across Singapore, Australia, and China for new co-working laboratory space projects, reflecting the Group’s continued efforts to broaden its revenue stream and capture new regional opportunities.

Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said,

“We will continue our current focus on expanding the laboratory construction and co-working laboratory space businesses, both of which are currently cash flow positive with promising long-term prospects amidst an encouraging flow of business opportunities and projects in the last twelve months.”

The Group’s co-working laboratory space segment contributed positively to AcroMeta’s FY2023 results and will be developed as a new engine of growth for the Group’s business moving forward.

While the Group’s continuing operations delivered a profit of S$2.2 million, the Group reported a net loss attributable to owners of S$7.5 million in FY2023 due to the one-off impairment and provisions. Excluding these, the net profit would be S$2.3 million compared to FY2022 net profit of S$2.9 million.

The one-off impairment and provisions relating to discontinuing operations related to renewable energy business are based on historical expenditure and have minimal impact on the Group’s ongoing cashflow. The Group’s net asset value remains positive at S$2.6 million or 0.93 cents per share as at 30 September 2023 while the Group’s cash and cash equivalents are stable at S$4.4 million as at 30 September 2023 as compared to S$4.1 million as at 30 September 2022. The proposed subscription of 12,500,000 shares in the capital of the Company for S$0.5 million, announced in November 2023, is expected to further strengthen the Group’s financial resources.

While renewable energy business is fundamentally promising, the Covid-19 pandemic’s impact on construction as well as regulatory changes meant that the project would continue to require financial support and affect the Group’s allocation of resources. The Group’s prudent step to place Neo Tiew Power Pte. Ltd. (“NTP”), a loss-making indirect subsidiary, under Creditors’ Voluntary Winding Up will enable optimal allocation of resources as the Group continues to progress forward with its specialist engineering and co-working laboratory space business.

This press release should be read in conjunction with the financial statements released by AcroMeta Group Limited today.

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.

ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The Company has been listed on the Catalist Board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:

ACROMETA Group Limited
Ms. Cheah Lai Min
Chief Financial Officer
Tel: +65 6415 0574
Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd
Mr. Wayne Koo
Tel: +65 6958 8008 / +65 9338 8166
Email: wayne.koo@waterbrooks.com.sg
Email: query@waterbrooks.com.sg

This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.

LAC and ART:DIS Collaborates on Exclusive Limited-Edition Umbrellas: A Celebration of Artists Overcoming Disabilities

SINGAPORE, Nov 28, 2023 – (ACN Newswire) – LAC, one of Asia’s leading health and wellness supplement brands, is proud to partner with ART:DIS (Arts & Disability Singapore) for a special festive initiative. As part of their year-end promotion, LAC will be distributing 40,000 limited-edition umbrellas featuring exclusive artworks from 4 talented artists with disabilities – Eugene Soh, Wesley Seah, Ling Teck Mong, and Gregory Burns.

Working with gifted talents locally, ART:DIS is an organisation that champions the cause of individuals with disabilities in the arts sector. Through fostering artistic skills and providing support through structured programmes, ART:DIS not only empowers these gifted artists to voice their unique perspectives, but also offers avenues to transform their passion into sustainable livelihoods.

Through this collaboration, LAC hopes to spotlight the extraordinary talents of these artists, raise awareness about the importance of inclusivity in the arts, and inspire communities to embrace and support individuals with disabilities in their pursuit of passion and profession this festive season. This is also reflected in LAC’s hiring practices, where they currently have 11 employees who are deaf and mute, who have been part of the company for as long as 18 years.

Celebrating Artists From Different Backgrounds

LAC is set to produce 10,000 umbrellas for each design created by the featured artists, and these will be distributed to customers throughout November and December. With a total of 4 distinct designs, one from each artist, LAC will rotate the featured design every two weeks.

In an effort to spotlight the artists, LAC aims to leverage this opportunity to amplify the personalities behind the artworks, offering them a platform to showcase their work to a broader audience.

Abstract – Loyal Blue by Eugene Soh

Eugene, once a physically fit individual faced physical challenges as a result of spinal complications but turned to art for solace. Aa a self-taught artist with a Mathematics degree from the National University of Singapore, he has become a highly sought-after impressionist artist, known for his ethereal works inspired by his deep faith and the works of masters such as Van Gogh.

Fixture of Dreams by Wesley Seah

Once a successful head-hunter with full sight, Wesley faced a life-altering challenge with a rare glaucoma condition, leaving him almost blind. Undeterred, he channeled his resilience into mastering Chinese Ink painting, a therapeutic outlet he discovered in 2015. After refining his skills at LASALLE College of the Arts, Wesley’s evocative art, characterised by dynamic strokes, now extends to colourful acrylic mediums, making him a standout talent at ART:DIS.

Fighting Fish by Ling Teck Mong

From a childhood passion for comic drawing, Teck Mong faced life-changing paralysis from a 1981 road accident. Rather than succumbing to adversity, he immersed himself in art, refining his skills through ART:DIS. Today, his journey of resilience shines through a vibrant portfolio of colored paintings.

East to West Lily by Gregory Burns

Gregory Burns is a Paralympic swimmer with four world records. His artistic journey began in Paris and took root during university, further blossoming during extensive travels through Asia, where he was deeply influenced by the region’s religious and architectural imagery. Completing his Master of Fine Art from the Royal Melbourne Institute of Technology in 1999, this internationally-acclaimed artist, featured on outlets like BBC, Time Magazine, and CCTV, has showcased his work in over 80 exhibitions worldwide, capturing the resilience of the human spirit.

Cynthia Poa, CEO of LAC Global, said of the campaign: “As we approach the festive season, a time of giving and reflection, we at LAC wanted to champion a cause that resonates deeply with us. We chose to support ART:DIS for their admirable mission of empowering artists with disabilities, and our goal is to celebrate the spirit of the season by showcasing these incredible talents. Through this collaboration, we aspire to not only delight our customers but also to amplify the message of inclusivity, diversity, and the enduring beauty of perseverance in the arts.”

Promotion Mechanics & LAC’s Christmas Sale

To own one of these limited-edition UV-protected umbrellas, customers will need to make a minimum purchase of $198 either online or in-stores between 1st November to 31st December to receive the umbrella as a complimentary gift.

Coinciding with LAC’s Christmas Sale which will run throughout November, customers will have the opportunity to stock up on their favourite LAC products or present them as gifts to loved ones with up to 48% off storewide when they purchase 4 items. Receive 28% off on the first and second products, 38% off the third, and 48% off the fourth product to save big while supporting these artists by raising awareness of their artworks.

Kerry Logistics Network Teams Up with EC Healthcare To Provide a Full Suite of Integrated Medical Logistics Management Services

HONG KONG, Nov 27, 2023 – (ACN Newswire) – Kerry Logistics Network Limited (‘Kerry Logistics Network’, ‘KLN’; Stock Code 0636.HK) has entered into a strategic cooperation agreement with EC Healthcare (Stock Code 2138.HK), Hong Kong’s largest publicly listed non-hospital medical service provider, to provide a comprehensive suite of integrated medical logistics management services. The companies held an agreement signing ceremony in Hong Kong on 24 Nov 2023.

Under the strategic cooperation, KLN will set up a centralised warehouse to consolidate EC Healthcare’s inventory management and provide customised logistics solutions including IT system integration, point-to-point delivery and a wide variety of value-added services on a long-term basis to support EC Healthcare’s business growth. In addition, KLN will manage the global sourcing, including the procurement processes of pharmaceutical products and the supply of medical devices for EC Healthcare.

Samuel Lau, Managing Director – Integrated Logistics North Asia of Kerry Logistics Network, said, “We are delighted to begin our relationship with EC Healthcare and to meet EC Healthcare’s logistics and procurement needs as a centralised service provider and manager. Not only will this strategic cooperation streamline EC Healthcare’s supply chain and provide it with a value-added end-to-end logistics solution that optimises its efficiency and medicine distribution to patients, but it will also showcase KLN’s capabilities and expertise in pharmaceutical logistics.”

Leslie Lu, Executive Director and Chief Executive Officer of EC Healthcare, said, “As the leading non-hospital healthcare service provider in Hong Kong, we strive to provide accessible, affordable, and sustainable preventive and precision healthcare services to more people. Drawing upon KLN’s expertise in supply chain management, we will gradually centralise our procurement and inventory management processes across our service network. This initiative aims to ensure a high-quality customer experience, maintain safe and well-regulated operations, while simultaneously achieving cost savings and improving operational efficiency.”

A top provider of Integrated Logistics (IL) services, KLN’s IL operation serves industry-leading corporations from myriad verticals ranging from electronics, food and beverage, fashion and lifestyle to pharmaceutical and healthcare, as well as provides best-in-class cold chain solutions, professional warehousing and distribution, domestic road freight, and other services.

Ellis Cheng, Executive Director and Chief Financial Officer of Kerry Logistics Network (middle left), Samuel Lau, Managing Director – Integrated Logistics North Asia of Kerry Logistics Network (left), Leslie Lu, Executive Director and Chief Executive Officer of EC Healthcare (middle right) and Andrew Wong, Chief Operating Officer of EC Healthcare (right) at the agreement signing ceremony on 24 November 2023.

About Kerry Logistics Network Limited (Stock Code 0636.HK)

Kerry Logistics Network is an Asia-based, global 3PL with a highly diversified business portfolio and the strongest coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal), e-commerce and express to industrial project logistics and infrastructure investment.

With a global presence across 59 countries and territories, Kerry Logistics Network has established a solid foothold in half of the world’s emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.

Kerry Logistics Network generated a revenue of over HK$86.6 billion in 2022. It is listed on the Hong Kong Stock Exchange as well as a constituent of the Hang Seng Corporate Sustainability Benchmark Index.

About EC Healthcare (Stock Code 2138.HK)

EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, which is listed on the Main Board of Stock Exchange of Hong Kong. EC Healthcare provides a one-stop medical and healthcare services in Greater China, including health checkups, vaccinations, lab testing, imaging diagnostics, primary care, specialist consultations, dental care, and pain management. It also provides aesthetic medical, beauty, wellness and veterinary services.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2022

For media enquiries please contact:

Prudence Lai / Karen Chu / Kelvin Man / Bob Tong

Cornerstones Communications Ltd

T 852 2903 9291 / 2903 9213 / 2903 9288 / 2903 9285

M 852 9465 3856 / 6171 3530 / 6849 9983 / 9296 0255

E kerrylogistics@cscspr.com

OrbusNeich Acquires 84% Stake in an Indonesian Distributor for Approximately US$15 Million

HONG KONG, Nov 27, 2023 – (ACN Newswire) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, is pleased to announce that it has acquired 84% of the issued share capital of PT Revass Utama Medika (“PT Revass”), through its wholly-owned subsidiary on 27 November 2023. The initial estimated consideration for this transaction is US$15.12 million, and the actual consideration, which is expected to be in the range of US$10.08 million to US$20.16 million, will be determined based on the actual profit recorded by PT Revass in FY2023. The consideration for the acquisition will be funded from the proceeds of the Group’s global offering and cash generated from operations.

PT Revass is an Indonesian company that specializes in the distribution and sale of cardiovascular intervention, neuro intervention, peripheral intervention and continuous renal replacement therapy products. Its profit after tax in FY2022 amounted to IDR14.3 billion (equivalent to approximately US$920,000). As of 30 June 2023, its unaudited net asset value was approximately IDR88.1 billion (equivalent to approximately US$5.7 million).(1) Upon completion of the acquisition, PT Revass will become an indirect non-wholly-owned subsidiary of the Group and its financial results will be consolidated into the Group’s financial statements.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “PT Revass has been engaged in the sales and distribution of medical devices in Indonesia for more than 10 years. After years of hard work, it has established a strong sales network in the country, covering more than 200 cardiac catheterization laboratories, and is well known in the medical industry. With the acquisition of PT Revass, the Group will shift from a distribution model to a direct sales model in the Indonesian market. This will not only directly increase the Group’s revenue and profitability, but also effectively accelerate our further penetration in this fast-growing economy with a huge population.”

Mr. Andriatno Martono, President Director of PT Revass stated, “We are honored to reach a sale and purchase agreement with OrbusNeich, the world’s leading manufacturer of PCI and PTA interventional devices. Both OrbusNeich and PT Revass are committed to providing patients with high-quality medical equipment and treatments. Under the leadership of OrbusNeich, which has rich marketing experience in the international market and high-quality and innovative products, we will be able to introduce more high-quality vascular interventional medical devices to the Indonesian market and benefit more patients there.”

Since introducing the first balloon product, Sapphire, to the Indonesian market in 2010, OrbusNeich is committed to increasing local market penetration by organizing education activities for doctors and continuously updating its product portfolio. In FY2022, the Indonesian market contributed to the Group US$3.1 million in revenue, representing a year-on-year increase of 29.6% and accounting for 2.2% of the total revenue. According to data from the World Bank, Indonesia’s population reached 276 million in 2022, making it the fourth most populous country in the world. In addition, according to the World Health Organization, ischemic and hypertensive heart disease is the second leading cause of death in Indonesia. With steady economic growth, Indonesia’s healthcare expenditure as a percentage of GDP has been increasing year after year. The number of cardiac catheterization laboratories for PCI procedures has also been increasing yearly and is expected to increase continuously in the future. Therefore, the Group believes that this transaction will be a sustainable growth driver for its future revenue and profit.

(1) At the rate of IDR10,000 to US$0.64

About PT Revass Utama Medika

Founded in 2010, PT Revass Utama Medika is a company engaged in the distribution and marketing of cardiology intervention medical devices. Initially, it began as an importer and distributor of stents and balloons from OrbusNeich. To encourage growth, PT Revass Utama Medika expanded its business by distributing other medical accessories as supporting devices for cardiology intervention. Moreover, the company created a large sales network spanning 30 major cities across the Indonesian archipelago. Consistent with its vision to be a trusted and leading business partner, PT Revass Utama Medika provides the highest quality cardiology intervention medical devices in Indonesia.

For more information, please visit the Company’s official website: https://www.revassutamamedika.com/

About OrbusNeich Medical Group Holdings Limited

OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease. As of June 30 2023, OrbusNeich has more than 210 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/

Perfect Medical Announces Interim Results for FY2023/24

HONG KONG, Nov 24, 2023 – (ACN Newswire) – Perfect Medical Health Management Limited (the “Company”, Stock Code: 1830.HK), one of the largest aesthetic medical operators in the world, together with its subsidiaries (collectively referred to the “Group”), is pleased to announce its interim results for the six months ended 30 September 2023.

RESULTS HIGHLIGHTS

— The Group’s revenue increased by 7.5% to HK$718.1 million, thanks to the momentum growth in revenue in Hong Kong and mainland China amid the abatement of the pandemic in early 2023.

— The Group’s EBITDA increased by 5.4% to HK$242.1 million.

— The Group’s net profit increased by 10.4% to HK$166.4 million, representing a net profit margin of 23.2%. Basic earnings per share were HK13.2 cents. If excluding the one-off government subsidies in the last financial period, the adjusted net profit after tax increased by 27.1%.

— The Board recommends the payment of an interim dividend of HK13.2 cents and a special dividend of HK1.0 cents per share to shareholders.

— The Group operated a total service area of 297,000 square feet in Hong Kong, mainland China, Macau, Australia and Singapore, with an addition of two shops in Hong Kong during the period.

For the period under review, the Group achieved satisfactory results thanks to the meaningful return of new customers and the solid relationship with the loyal customers in both Hong Kong and mainland China. The Group’s revenue increased by 7.5% year-on-year to HK$718.1 million (FY2022/23 interim: HK$668.3 million). The Group’s EBITDA increased by 5.4% year-on-year to HK$242.1 million (FY2022/23 interim: HK$229.7 million). Profit attributable to equity holders of the Company was HK$166.4 million, increased by 10.4% year-on-year (FY2022/23 interim: HK$150.7 million), representing an increase of 0.7 percentage points in net profit margin to 23.2% for the period (FY2022/23 interim: 22.5%). Basic earnings per share were HK13.2 cents (FY2022/23 interim: HK12.1 cents).

As of 30 September 2023, the Group operated a total service area of 297,000 square feet in Hong Kong, mainland China and overseas.

Hong Kong Operation

Revenue from Hong Kong operation increased by 11.6% year-on-year to HK$549.6 million (FY2022/23 interim: HK$492.4 million), overtaking the revenue of Hong Kong operation before pandemic in FY2019/20 interim by 7.2%, thanks to the improvement in shop utilisation and the contribution from the newly established residential shops in Hong Kong. The recovery of revenue to beyond the FY2019/20 interim level demonstrates the Group’s success in recalibrating its business operation. Currently, revenue from Hong Kong operation accounted for 76.5% of the Group’s revenue (FY2022/23 interim: 73.7%).

As of 30 September 2023, the Group had a well-established network of service centres in Hong Kong covering a total service area of 192,000 square feet, with an increase of two shops in Tsuen Wan and Taikoo during the period.

During the period, the Group witnessed a strong demand for its core aesthetic medical services thanks to the unwavering support by its loyal customers. The Group has recalibrated its business model to further expand its geographical reach in Hong Kong through the introduction of residential shops in medium-to-high end shopping malls and residential locations. As for the core mega shops, the Group saw a welcoming response to the medical tourism flagship centres in Causeway Bay and Tsim Sha Tsui where there was intense demand for its premium medical beauty services by the cross-border customers.

At its non-aesthetic medical business, it includes a range of supplementary healthcare management services, including hair growth treatment, pain treatment, health screening service as well as other beauty and wellness services, to fully collaborate with our aesthetic medical services. During the period, the Group enhanced the cross-selling to the medical business following the improvement in our aesthetic medical business.

Regions outside Hong Kong

Revenue from regions outside Hong Kong decreased by 4.2% year-on-year to HK$168.5 million (FY2022/23 interim: HK$175.9 million), impacted by the lower demand in Singapore and Australia but compensated by the recovery in mainland China. Currently, revenue from the regions outside Hong Kong accounted for 23.5% of the Group’s revenue (FY2022/23 interim: 26.3%).

For the period under review, operating profit in mainland China and Macau improved year-on-year thanks to the gradual recovery in customers’ demand and the absence of business suspension in this financial period. As of 30 September 2023, the Group had a network of 22 shops in strategic locations in mainland China and Macau. In the first half of this financial year, the performance of the Australia and Singapore operation was impacted by the sustained inflationary environment and the high living expenses in both countries. It may take some time for the international market to recover.

Prospects

Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of Perfect Medical, said that “The promising business performance in the first half of the financial year has demonstrated our superior business model can withstand poor market conditions. We remained steadfast in our core strategy of ‘Healthcare + Medical Beauty’ to satisfy the individual needs of the consumers.

As the demand generally bounced back after the three-year pandemic, the rebound in tourist arrivals in Hong Kong this year will bring along additional cross-border customers to the Group, which will reinforce the Group’s determination to become the most favourable aesthetic medical service centres in the Greater Bay Area in the long run.

In mainland China, we will closely monitor the market dynamics and economic landscape to better prepare for the economic fluctuation. We spare no effort in optimising our business operation to improve shop productivity to fully capitalise on the rebound in foot traffic at shopping malls. As for the international market, we will proceed with its business development in a prudent and steady manner with relentless dedication to customer satisfaction.”

For further information of the Group’s FY2023/24 interim results, please refer to the Company’s Interim Results Announcement on the Hong Kong Stock Exchange website at: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1124/2023112400233.pdf

About Perfect Medical Health Management Limited

Perfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical operators in the world established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 297,000 square feet as of 30 September 2023. Its operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company was included as a constituent stock of the MSCI Hong Kong Small Cap Index on 27 May 2021, demonstrating the confidence from the capital market and recognising the investment value of the Company.

For further information, please contact:

Perfect Medical Health Management Limited

Marco So / Peter Kwok

Email: ir@perfectmedical.com

Tel: (852) 2770 2099

iPR Ogilvy Limited

Callis Lau / Tina Law / Rita Chen

Email: perfectmedical@iprogilvy.com

Tel: (852) 2136 6185

OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG

HONG KONG, Nov 23, 2023 – (ACN Newswire) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced the acquisition of 100% interest in Eucatech AG, a German company principally engaged in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular projects, for EUR2,400,000. Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are pleased to announce the acquisition of Eucatech AG, a company with two decades of experience and a shared mission with OrbusNeich. We believe that this acquisition will enrich our product portfolio. In particular, its CE marked products, including coronary stent with sirolimus coating, peripheral self-expandable stent and paclitaxel-coated PTCA and PTA balloons will enhance our ability to treat lesions in PCI and PTA procedures. In addition, by leveraging our strong sales network, these cutting-edge products are expected to drive growth and further fulfill our commitment to improving the quality of life of patients through innovative technologies by extending their benefits to a wider population.”

Since its successful listing last year, the Group has actively pursued opportunities to strengthen its business. The incorporation of Eucatech AG’s innovative and high-caliber products will bring about technological synergies while allowing the Group to stay ahead of market trends. Therefore, the Group views this acquisition as a strategic move to reinforce its market presence and distribution network .

The Group has demonstrated its unwavering commitment to accelerating business expansion following its listing. Such initiatives include the extension of an exclusive U.S. distribution agreement with Abbott Laboratories’ CSI in September to increase U.S. market penetration, the initiation of a clinical trial for Scoreflex TRIO in the PRC in May for product development, and the establishment of its largest R&D and production base in Hangzhou, the PRC, which is expected to commence construction by the end of 2023, to increase R&D and production capacity.

About Eucatech AG

Headquartered in Weil am Rhein, Eucatech AG is a German medical engineering company specializing in the development, manufacture, and sale of minimally invasive cardiovascular and endovascular products. Since 1997, it has been providing innovative product solutions to improve patients’ quality of life, including the CE Mark certified EucaLimus Sirolimus Eluting Coronary Stent System, SUPPORT C Paclitaxel Coated Coronary Balloon Catheter, Resistant Peripheral Self-Expandable Stent System and VITUS Paclitaxel Coated PTA Balloon Catheter.

For more information, please visit Eucatech AG’s official website: https://eucatech.de/en/home

About OrbusNeich Medical Group Holdings Limited

OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease. As of 30 June 2023, OrbusNeich has more than 210 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/

JBM Healthcare Announces FY2024 Interim Results

HONG KONG, Nov 22, 2023 – JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the interim results of the Group for the six months ended 30 September 2023 (the “Reporting Period”).

KEY HIGHLIGHTS

— Revenue up by 38.0% to HK$326.8 million

— Gross profit increased by 100.1% to HK$171.1 million

— Profit attributable to equity shareholders almost tripled to HK$62.5 million

— Gross profit margin significantly improved from 36.1% to 52.4%

— Interim dividend of HK3.45 cents per share

— Household brands Po Chai Pills and Ho Chai Kung achieved impressive growth

— Portfolio witnessed positive momentum across all segments amid continued market recovery

During the Reporting Period, the Group’s branded healthcare business achieved a remarkable total revenue of HK$326.8 million, demonstrating an impressive period-on-period growth of 38.0%. The Group’s gross profit for the same period reached HK$171.1 million, marking a substantial increase of 100.1%. In the first half of fiscal year 2024, the consolidated profit attributable to equity shareholders amounted to HK$62.5 million, nearly three times that of the corresponding period last year.

Furthermore, the gross profit margin notably improved, rising from 36.1% in the same period last year to 52.4% in the Reporting Period. These financial results underscore the robust performance and significant growth achieved by the Group’s branded healthcare business.

The outstanding performance can be attributed primarily to favorable market sentiment, the resurgence of Mainland visitor arrivals following the lifting of pandemic-related restrictions in Hong Kong and the Mainland earlier this year, and the effective implementation of the Group’s brand management strategies. These strategies played a pivotal role in augmenting sales revenue and improving profit margins.

The Board declares the payment of an interim dividend of HK3.45 cents per share.

Market-Oriented Portfolio and Effective Brand Management Fueled Robust Performance

In the branded medicines business, sales revenue achieved a remarkable growth of 85.4%, primarily attributable to the exceptional performance of Ho Chai Kung products. A widely recognised household name in over-the-counter painkillers and fever relief, Ho Chai Kung has experienced a significant increase in sales due to its effective brand development strategy, capitalising on the retail market rebound following the easing of pandemic-related restrictions. The brand’s recent launch of a new TV advertising campaign featuring celebrity endorser Hins Cheung, has received tremendous response from the audience. The creative campaign, “Trust Hin Gong, Use Ho Chai Kung”, garnered substantial views and likes across various social media platforms, creating a trending topic in the city and significantly enhancing the brand’s visibility in Hong Kong.

For the proprietary Chinese medicines segment, sales increased by 14.3% in the Reporting Period, underscored by the solid momentum of its Concentrated Chinese Medicine Granules (“CCMG”) business alongside the exceptional growth of Po Chai Pills. To solidify its leading position in the Chinese gastrointestinal medicine sector and appeal to a younger audience, Po Chai Pills also successfully launched a new creative TV advertisement titled “Ivana’s Po Chai Pills Digestive Tune”. This campaign features the renowned singer-songwriter and musician Ivana Wong, who rides onher melodious voice to a reimagined and reworded rendition of the classic Po Chai Pills jingle.

In the health and wellness products segment, sales revenue experienced a notable growth of 107.1%. Earlier in the year, the Group completed the acquisition of the supplement brands “Seasons” and “Slimming Expert”, thereby reinforcing its position in the health supplement retail market.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, stated, “Looking ahead, the retail market in Hong Kong is anticipated to sustain its positive momentum in the second half of the financial year, and JBM Healthcare is well positioned to leverage the growth opportunities.”

“We have made consistent strides in advancing our strategic priorities to drive business development. This encompasses expanding our local and cross-border e-commerce platforms, exploring opportunities in the traditional Chinese medicines (TCM) sector in Hong Kong and the expanding Greater Bay Area market, adapting our product portfolio to align with evolving consumer preferences, and enhancing our commercial execution to optimise results.”

About JBM (Healthcare) Limited (Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers’ healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma for Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk

For media inquiries, please contact:

Strategic Financial Relations Limited

Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk

Rachel Ko Tel: (852) 2114 2370 Email: rachel.ko@sprg.com.hk

Katrina Hui Tel: (852) 2114 4318 Email: katrina.hui@sprg.com.hk

Fax: (852) 2527 1196

Singapore’s Largest Brick-and-Mortar Nutrition Brand LAC Launches Nutrition for Life Campaign, Advocates Holistic Wellness with Minimal Effort

SINGAPORE, Nov 21, 2023 – (ACN Newswire) – Singapore’s largest brick-and-mortar supplement brand, LAC, Leader in Antioxidative Control™, announced the launch of its Nutrition for Life campaign to encourage Singaporeans of all ages to prioritise not only their physical health but also their mental and emotional well-being. This is the first LAC-branded event since the health and wellness brand opened 54 physical stores in Singapore, further increasing its footprint in the region.

Nearly 90% of Singaporeans have indicated that the COVID pandemic has prompted them to reassess their lives, with 41% expressing increased concerns about health issues and the importance of staying healthy. However, the same group of people are finding troubles to do so – the lack of time is seen as the biggest obstacle to manage physical, mental and emotional well-being amongst Singaporeans. In a recent study, more than half of mothers (51%) expressed feelings of stress or finding it challenging to cope, mainly due to juggling between household, work and family responsibilities. Additionally, almost half of all women struggle to allocate time for their physical, mental, and emotional well-being, a sentiment that is also shared by 32% of men.

Taking cue from this pressing need for holistic wellness solutions, LAC’s Nutrition for Life campaign features a range of proprietary blends of supplements aimed to help Singaporeans incorporate supplements into their daily lifestyle to not only improve their physical health, but also to bridge nutritional gaps, manage stress levels and achieve overall holistic health.

“The Nutrition for Life campaign embodies LAC’s commitment to inspire Singaporeans to lead healthier and more fulfilling lifestyles. We believe in empowering individuals to prioritise not just physical health but also mental and emotional well-being. Our range of proprietary blends is a step towards helping people seamlessly incorporate supplements into their daily lives. Instead of popping multiple pills, these exclusive blends formulated with scientifically-proven ingredients encourage easy and fuss-free consumption with just one single supplement that can be consumed on-the-go for multi-hatting Singaporeans,” says Cynthia Poa, CEO, LAC Global.

LAC MASQUELIER’s® French Pine Bark Extract: SUPER ANTIOXIDANT, Perfect for Immunity Boosting

Start the day with Masquelier’s French Pine Bark. As LAC’s best-selling product, over 200,000,000 boxes of Masquelier’s French Pine Bark have been sold worldwide. This gem of a pill offers a holistic approach to beauty that goes beyond superficial enhancements, LAC MASQUELIER’s® French Pine Bark Extract antioxidant work from within, helping individuals to counteract oxidative stress and free radicals that can contribute to premature ageing and other skin-related concerns. Loaded with oligomeric proanthocyanidins (OPCs), a potent antioxidant, the product reduces the amount of free radicals in the body, allowing the body to combat pathogens and infections effectively.

LAC Activated Liver Protector: Promoting Liver Health for Better Sleep and Skin

Persistent issues that seem trivial and insignificant, such as itchy skin, with or without the onset of eczema, along with chronic fatigue, could also spell liver issues. Contrary to popular belief, poor liver function does not just affect those who consume alcohol. Excessive consumption of fatty foods and even long term medication can also stress and burden the liver, weakening its functions and increasing the risk of liver disease. The LAC Activated Liver Protector is a blend of Traditional Chinese Medicinal herbs that can prevent and relieve fatty liver, promote healthy liver function and lower bad blood lipid levels, infused with ingredients such as Hawthorn fruits, lotus leaves, and chrysanthemum flowers to keep the liver healthy.

LAC BrainSpeed: Perfect for Mental Clarity & Concentration

Managing multiple roles often causes us to lose focus and concentration. Also, as we age, so do our brains.

LAC® BrainSpeed invigorates the brain for optimal mental performance with its advanced brain formula. Made with nourishing ingredients containing Ginkgo leaf extract with 24% Ginkgo flavone glycosides and Vitamin B3, BrainSpeed is the perfect supplement to energise the brain by promoting blood and oxygen circulation.

Fast-acting and effective, this energising formula is packaged into caplets. With only a simple step added to our daily regime, BrainSpeed helps the busiest people reduce instances of forgetfulness, promotes ability to cope with mental stress and healthy mood balance, allowing them to take on the world.

LAC Probiotic Complex: Perfect for Gastrointestinal Health

In order to restore good intestinal gut flora, and boost overall gastrointestinal health, LAC introduces the LAC Probiotic Complex, further enhanced with fermented yeast and olive fruit essence to further promote stronger immune responses. It contains 6 strains of Lactobacillus and Bifidobacterium, known as the “good bacteria”, to promote more diverse good bacterial growth within the gut. Infused with indigestible maltodextrin, it acts as a prebiotic to flourish the good bacteria in the intestines, providing support for digestive discomfort and nourishing your gut health from within.

LAC Junior: LAC BrainSpeed® Junior and LAC Probiotic Junior Jelly

Packed with brain-enhancing ingredients like Omega-3 fatty acids DHA and EPA, Phosphatidylserine, and Vitamin B1, the combination of these scientifically proven nutrients in LAC’s BrainSpeed® Junior help to enhance cognitive ability and brain chemical formation to improve brain focus and promote memory. Coupled with other beneficial ingredients such as Vitamin C and Isomaltooligosaccharide, the product provides all-rounded protection for the body and mind, improving adaptation to stress and supporting gastrointestinal and digestive health.

Loaded with 12.5 billion active probiotic cells and a blend of 26 fermented vegetable fruit complex, LAC’s Probiotic Junior Jelly is a delicious and convenient way to support your child’s gut health and digestion. A potent ally for your child’s health, a strong and balanced gut can help in building a resilient immune system, minimising the risk of illnesses, especially crucial during pivotal moments like exams when falling sick can derail their preparations and performance.

Acrometa Subsidiary Signs Two MOUs to Develop Co-Working Laboratory Space Business in China

SHANGHAI, CHINA, Nov 17, 2023 – (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that its 70% owned subsidiary Life Science Incubator Holdings Pte Ltd (“LSI”) has entered into a strategic partnership with Fenglin Healthcare Industry Development (Group) Co. Ltd. (“Fenglin Group”) through a non-binding Memorandum of Understanding (“Fenglin MOU”) to develop new business opportunities for co-working laboratory space in the People’s Republic of China.

(Front L-R) Fenglin Group Deputy General Manager Mr Pan Taishen and AcroMeta Chairman Mr Levin Lee Keng Weng at the signing ceremony in Shanghai.

China-incorporated Fenglin Group, the administrative arm of the Shanghai Xuhui government in charge of Life Sciences, aims to establish an integrated ecosystem of local and international stakeholders in Shanghai’s Xuhui District to accelerate biopharmaceutical innovation and development.

Fenglin Group will promote the co-working laboratory space with a focus on overseas biomedical science startups and SMEs planning to develop their business in China. On its part, LSI will use its existing business networks to recommend to Fenglin Group, Singapore and other overseas biomedical sciences companies that intend to have a business foothold in China and need co-working laboratory space. An area of approximately 2,705 sqm is set to be leased by LSI at preferential rates to set up world-class co-working laboratory space at Fenglin Group’s Innovation Valley Life Sciences Hub to provide a cost-effective venue with comprehensive laboratory facilities and equipment for research and development.

Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said,

“AcroMeta will continue to capture business opportunities both in Singapore and beyond to grow and create sustainable shareholder value for its investors. The business model for the Group’s co-working laboratory space business is scalable and replicable and therefore eminently suitable for international expansion.”

“China’s biopharmaceutical industry has undergone a tremendous transformation to become a thriving innovative life sciences hub driven by investments in research and development. The sector is a key focus of the Chinese government’s Made in China 2025 strategy, and we are optimistic about LSI’s long-term growth potential in collaboration with local partners.”

LSI has also signed a non-binding Memorandum of Understanding (“JV MOU”) with three investor parties (“Investor Parties”) for the setting up of a Joint Venture company (“JV Company”) to define the structure, ownership, and operational aspects of the Fenglin MOU. The expected JV Company will have a paid-up capital of at least S$3 million, with LSI holding a 51% stake. The Investor Parties are all established businessmen with deep connections to China’s medical and life science industries and will contribute their business network, expertise, and experience to facilitate the smooth set-up and successful realisation of the Fenglin MOU’s objectives.

The Fenglin MOU reflects the Group’s continued efforts to broaden its revenue stream and capture new regional opportunities. Following the Group’s MOU for the supply of high-grade silica sand from Indonesia, AcroMeta has extended its MOU with its Thai partner to jointly pursue the design, construction and operation of a solid waste and sludge testing and certification laboratory.

Reference:

https://links.sgx.com/FileOpen/PR-AcroMeta%20signs%20two%20MOUs%20for%20Co-working%20Lab%20Space%20Biz%20in%20China.ashx?App=Announcement&FileID=778491

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.

The Company has been listed on the Catalist Board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:
ACROMETA Group Limited
Ms. Cheah Lai Min
Chief Financial Officer
Tel: +65 6415 0574
Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd
Mr. Wayne Koo
Tel: +65 6958 8008 / +65 9338 8166
Email: wayne.koo@waterbrooks.com.sg
Email: query@waterbrooks.com.sg

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com

The Largest Biotech City in Europe Will Soon Be Built, With an Investment Amounting to 7 Billion Euros

VILNIUS, Lithuania, Nov 17, 2023 – (ACN Newswire) – Northway Group is embarking on a project to establish Europe’s largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes – 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres – that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.

Northway Group is in the process of constructing Europe’s largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.

“A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania’s long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania’s innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion,” says the President of the Republic of Lithuania, Gitanas Nausėda.

Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania’s strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania’s prominence in the international biotech sphere.

The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. “Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges,” says Viktorija Čmilytė-Nielsen.

Vision of BIO CITY: A European Biotechnology Leader

“We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape,” said Prof. V. A. Bumelis.

Gene Therapy Centre will Open in 2024

The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group’s subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania’s role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.

“Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations,” added Prof. V. A. Bumelis.

The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.

A Comprehensive Lithuanian Biotech Hub

By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.

“We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country’s competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture,” said Prof. V. A. Bumelis.

Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.

Lithuania is Among the Leaders in the Global Biotechnology Market

The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.

“Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life – we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions,” states Aušrinė Armonaitė, the Minister of the Economy and Innovation.

Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country’s GDP. The Northway group, a key player in Lithuania’s biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.

BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com